Table 2 iPSC-derived cellular agents for immunotherapy

National Cancer Institute (NCI)

iPSC T

T

Gastrointestinal Cancers

Breast Cancer

Pancreatic Cancer

Melanoma

Lung Cancer

1) Generation of an iPSC-derived thymic organoid

2) Cancer antigen-specific T-cells

Preclinical studies/NCT03407040

Fate Therapeutics

FT819

T

B-cell Malignancies

1) CAR19 1XX placed under the control of endogenous TCR activity;

2) TCR KO

Phase 1/NCT04629729

FT500

NK

Advanced solid tumors

–

Phase 1/NCT03841110

FT596

NK

r/rB Lymphoma

B-CLL

1) CD19 CAR

2) High-affinity 158 V, non-cleavable CD16 (hnCD16) Fc receptor

3) IL-15 receptor fusion (IL-15RF)

Phase 1/NCT04245722

FT516

NK

r/rAML

r/rB-cell lymphoma

Advanced solid tumors

hnCD16 Fc receptor

Phase 1 /NCT04551885/ NCT04023071

FT536

NK

–

1) MICA/B CAR

2) IL15RF

3) CD38 KO

Preclinical studies/-

FT538

NK

Advanced hematologic malignancies

1) hnCD16 Fc receptor

2) IL15RF

3) CD38 KO

Phase 1/NCT04614636

FT573

NK

Solid/hematologic malignancies

1) B7H3 CAR

2) hnCD16 Fc receptor

3) IL15RF

4) CD38 KO

Preclinical studies/-

FT576,

NK

MM

1) BCMA CAR

2) hnCD16 Fc receptor

3) IL15RF

4) CD38 KO

Preclinical studies/-

Allogene Therapeutics + Notch Therapeutics

iPSC-AlloCAR

T/NK

NHL

Leukemia

MM

Generating from synthetic Engineered Thymic Niche (ETN) platform

Preclinical studies/-

Century Therapeutics

–NTY-101

NK

r/r B-cell lymphoma

1) CD19 CAR

2) expressing soluble IL-15

3) EGFR safety switch

Preclinical studies/-

CNTY-103

NK

Recurrent glioblastoma

CD133 + EGFR CAR

Preclinical studies/-

CNTY-102

T/NK

r/rB-cell lymphoma

Other B-cell malignancies

CD19 + CD79b CAR

Preclinical studies/-

CNTY-104

T/NK

AML

Multi-specific

Preclinical studies/-

CiRA + Takeda

iCART

T

–

–

Preclinical studies/-

Cartherics

–

NK

ovarian cancer

1) TAG72 CAR

2) Delete immune suppression gene

3) Multiple anti-cancer functionality

Preclinical studies/-

–

T

–

CAR construct

Preclinical studies/-

Shoreline Biosciences

–

NK

–

–

Preclinical studies/-

–

Mac

–

–

Preclinical studies/-

CellOrigin

–

NK

Hematological malignancies

–

Preclinical studies/-

iPSC-CAR-Mac01/02/03/04

Mac

Solid Tumor

–

Preclinical studies/-

iPSC-CAR-NK01

NK

Solid tumor

–

Preclinical studies/-

HebeCell

–

NK

–

1) Generating from 3D bioreactors

2) CAR construction

Preclinical studies/-

Neukio Biotherapeutics

–

NK

–

CAR construction

Preclinical studies/-

nuwacell

–

T/NK

–

CAR construction

Preclinical studies/-

Biotheus + iCAMUN

iPSC-CAB-NK

NK

Solid tumor

–

Preclinical studies/-

PersonGen

iPS-CAR-NK

NK

–

CAR construction

Preclinical studies/-